Analysts raised their fair value estimate for California-based Pacific Biosciences to $2.50 from $2.36, a move based on a handful of updated assumptions rather than any sweeping change in the story. The discount rate used in their model has changed from 10.58% to 10.31%, and the long-term revenue growth assumption has been adjusted from 13.42% to 13.77%, reflecting slightly increased confidence in PacBio’s ability to grow if it continues to follow its business plan and product roadmap.
A key part of the bullish case you’re seeing has to do with renewed institutional focus, with Cathie Wood’s ARK Investment recently buying 1.03 million shares, which some analysts believe is consistent with a modest lift in fair value and revenue growth assumptions, while others believe this could be fragile support if sentiment shifts. At the same time, the lower discount rate in the latest model suggests that some analysts are more comfortable with PacBio’s risk profile than before, although cautious voices question whether this fully reflects execution and financing risks, which remain important for riskier genomics tool names.
In short, the move to $2.50 in fair value was based on a slightly more optimistic revenue trajectory and a small shift in the way risk is priced, with ARK’s purchases taking center stage in both the bullish and bearish narratives surrounding whether the optimism was justified. As this story continues to evolve, it’s worth knowing where to look for new model updates, institutional trading disclosures, and new commentary so you can stay on top of how the narrative about PacBio’s fair value continues to change.
Add Pacific Biosciences of California’s Fair Value to your watchlist or portfolio to stay informed as its fair value changes. Or, explore our community and discover new perspectives on California Pacific Biosciences.
🐂 Bullish Key Points
Recent buying activity by Cathie Wood’s ARK Investment (purchasing 1.03 million shares of PacBio stock) has been viewed by the research process as a supportive sign, suggesting that some institutional investors are seeing enough progress in execution and product focus to justify remaining invested.
Bulls tend to point to the growth potential associated with PacBio’s business plan and roadmap, and believe the ARK acquisition is consistent with slightly higher long-term revenue growth assumptions that are factored into the current fair value estimate of $2.50.
Supportive voices highlight PacBio’s execution and financing efforts as key drivers that can help it stay on its expected growth path, while still acknowledging that valuation and near-term volatility are part of the story for genomic tools stocks like this one.
More cautious analysts see a modest rise in fair value to $2.50, arguing that just small adjustments to discount rates and growth inputs could already reflect considerable upside, especially given ongoing execution and funding risks.
Skeptics also point out that ARK Investment’s acquisition could cut both ways, as it would focus attention on a single institution, which could prove fragile support if sentiment or capital flows change, exposing the stock to more volatile swings from news flows.
Do your thoughts align with bull or bear analysts? Maybe you think there’s more to this story. Head to the Simply Wall St community to discover more perspectives or start writing your own story!
Nasdaq GS: PACB 1-Year Stock Price Chart
Cathie Wood’s ARK Investment bought 1.03 million shares of PacBio, bringing new attention to the stock and sparking more discussion among institutional and retail investors about its risk-reward tradeoff.
PacBio launches CiFi, a community-developed method that pairs chromatin conformation capture with HiFi long-read sequencing. This method is designed to provide chromosome-scale, haplotype-resolved genome assemblies from a single Revio run for use in genome biology, biodiversity work, and functional genomics.
The company narrowed its full-year 2025 revenue guidance to $155 million to $160 million, citing third-quarter results as the reason for the updated range. This gives investors a tighter reference point when considering near-term expectations.
Through its collaboration with Berry Genetics, PacBio’s Sequel II CNDx System has received Class III medical device registration approval from the China National Medical Products Administration. This is described as the first regulatory clearance of a clinical-grade long-read sequencer for high-precision genomic testing. PacBio’s HiFi technology was also selected as the primary platform for the Korean Pan-Genome Reference Project, which targets more than 1,000 whole genomes.
Fair Value: Adjusted to $2.50 from $2.36, which analysts called a modest increase in target levels for the stock.
Discount rate: Adjusted slightly from 10.58% to 10.31%, slightly increasing the present value assigned to future cash flows in the model.
Revenue Growth: Revised to 13.77% from 13.42%, indicating slightly higher long-term growth assumed in the updated forecast.
Net profit margin: Stable at 15.66%, indicating that the latest round of profit assumptions has not changed.
Future price-to-earnings ratio: adjusted from 28.34 times to 29.57 times, representing a slight increase in the valuation multiple of California Pacific Biosciences’ expected earnings.
Narratives are short, structured stories that tie your opinion of the company to hard data. On Simply Wall St’s community page, you can list out what you think will happen to a company’s revenue, earnings, and margins, tie that to fair value, and then compare that to today’s price to help decide when to buy or sell. The narrative automatically updates as new news, guidance, or benefits come in, so your perspective stays current with no extra work.
Head to the Simply Wall St community to follow the California Pacific Biosciences narrative and see how the stories and numbers come together:
How global genomics projects, clinical laboratory adoption, and international programs using PacBio’s long-read HiFi platform impact recurring consumables revenue and future earnings assumptions.
Why current fair value, revenue growth, margins, discount rates, and future P/E ratios used in the original PacBio narrative form the backbone of analyst expectations.
What risks around financing, competition, cash burn and project concentration could challenge this story and impact how consistent fair value is with the current share price.
Curious how numbers become the stories that shape markets? Explore community narratives
This article from Simply Wall St is general in nature. We only use unbiased methodologies to provide commentary based on historical data and analyst forecasts, and our articles are not intended to provide financial advice. It does not constitute a recommendation to buy or sell any stock and does not take into account your objectives or your financial situation. Our goal is to provide you with long-term focused analysis driven by fundamental data. Please note that our analysis may not take into account the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any of the stocks mentioned.
